Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q30442046

about

Complement in monoclonal antibody therapy of cancer Dynamics of macrophage trogocytosis of rituximab-coated B cells Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategies Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL c Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?Antigenic modulation and rituximab resistance.Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.A general process for the development of peptide-based immunoassays for monoclonal antibodies.Rituximab: therapeutic benefit! Vitamin R?Ofatumumab, a human anti-CD20 monoclonal antibody.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Induction of interleukin-6 production by rituximab in human B cells.Rituximab mediates loss of CD19 on B cells in the absence of cell death.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).Anti-CD20 monoclonal antibodies: historical and future perspectives.Changing paradigms in the treatment of chronic lymphocytic leukemia.Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.CD4(+) T cell-released exosomes inhibit CD8(+) cytotoxic T-lymphocyte responses and antitumor immunity.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.Rituximab biosimilars.Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia.Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo.Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Maxed out macs: physiologic cell clearance as a function of macrophage phagocytic capacity.Antigen Loss Variants: Catching Hold of Escaping Foes.The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden.

P2860

Q26860800-BD7000EA-B168-41AA-A940-E17D6257CAD0 Q27314806-4D13F14E-F276-44A8-887E-34331949E0B8 Q27694769-6A6920EB-82F8-4CB5-989E-DFC2A2E1F037 Q30276243-7E95D8A9-0032-4141-8965-137178F4A86D Q30405847-602C450F-60E7-4832-8D9A-D60DEB668FFC Q30408922-ABACD3B6-27EA-4614-98B4-1C1BB9A44AA9 Q30417730-066F1637-ED46-4A86-863A-9E20581EB3B1 Q30421637-26950A79-E2A7-4688-B14E-56CBAF577869 Q30423909-A737501C-33A8-40CE-BBA9-3544CDABB80D Q30432874-5510B984-DA76-4A5A-A4C4-1C2C733CFBD7 Q30436996-2D44E021-3521-4216-B0D5-B8604CDA70CA Q30439017-17CD4B0B-7525-4CC9-9322-36C13ECF45EB Q30440293-1E6E694F-D646-4287-81AC-86737B142B4F Q30453680-8287C851-9001-4A4E-B65A-FD4A52C12E0F Q33525284-D44B3A33-2F72-4531-9F67-7561FC38AEA7 Q33764056-7E14EDC4-4F71-40AF-8714-1B3E3C837C4E Q34095311-7041FD8D-9F55-4D53-9CF0-55D0F407C640 Q34310845-410A0636-540F-4436-82F1-3A76EF5D8CFD Q34415869-D6B650D7-FF98-4B86-8E04-42A33F4F27BE Q36252683-D9C32A2F-FB6B-40BD-AF69-BA8CE7499D4C Q36437030-D901A41D-BFBB-4549-A5C8-B32E12893166 Q36725445-7C80672C-E408-4EF3-ADD1-7D492962F86F Q37601775-CC9FFB91-5F51-47F5-A76E-662526CFC145 Q37662198-6A7874FE-9A8B-4402-92D4-E46D650945B1 Q37676785-E03831F6-EB71-4FF4-9CCE-6F23953B8C93 Q37729257-220B7147-342B-43A5-BDCC-0416F2CF98D9 Q37843939-628B764B-B6E6-4DE4-96E1-D249B2D2C03D Q37919869-E985342B-36F5-4284-B91E-48774396A4A7 Q38068932-74CC6AAC-4216-4FB6-A1A6-6E35B6AAF1D6 Q38100232-F30D6B7F-56A5-4AF6-A270-9B52C3029442 Q38100787-9788DA62-67DA-4DD2-96FE-D5C8C1B35721 Q38271939-2DAAD868-AA64-4B63-A924-3A7550E15C74 Q38445357-45DB0B59-4460-40C9-9E45-AC1C786EAD20 Q38708447-9F119A56-F6F0-4656-A5C3-307F2D550313 Q38768387-36B1D789-FE3D-4B1F-B2A5-B8A6AE7FE410 Q38824182-774B6928-2A44-4132-A91E-4C2440B828F2 Q39004366-52741DCF-2093-4C35-A6F0-B8866488BFB5 Q39013196-828FE521-2CC1-4F63-9DB8-03C65E21A0A3 Q39175440-926C8D60-5B66-4FF7-B7A3-E564743A10BF Q39646209-F6253091-EA7D-4DE6-9BDB-5E97F99C2F5C

P2860

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q30442046

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@ast

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@en

type

label

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@ast

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@en

prefLabel

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@ast

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@en

P1433

Q30442046-7D24F014-BE3D-4F41-ACB4-35888A6E98FE

P1476

Q30442046-E589BAF6-C5B1-414B-AFD4-3D1CEE21492D

P2093

Q30442046-1677918C-868B-4F30-898B-8B54D51C1475

Q30442046-38EF3D13-DB94-40E2-A449-52B520F34AF8

Q30442046-7E541E1B-8EDB-4451-9CFB-EF7CE83E8D43

Q30442046-91FFB65C-B5F2-48DE-8915-052D3F492D30

Q30442046-A00C4E52-7770-4745-8927-6D59CD031C24

Q30442046-AFFE9038-0A80-4AA8-A24D-176ABB494FCF

Q30442046-B2431C9C-BA20-4CD9-988A-1C9266898E13

Q30442046-CC4475F2-FC81-4C14-984C-F8AB948AA81D

Q30442046-FBFED605-E399-48FA-95A2-D1063A69F477

P304

Q30442046-A134229F-B9EB-4CCB-9A17-A9EAFC338CC2

P31

Q30442046-FB8BD61E-D4E3-46DE-AF18-1E238EC211F5

P356

Q30442046-29BCA1CF-5D77-4C2D-A29E-95508085D4A7

P407

Q30442046-4DBE04C2-67CA-4E72-AFAB-0408EE0FCB5A

P433

Q30442046-1F872C55-2B21-4DE6-931A-9EA5EC48ABE2

P478

Q30442046-D3665D7C-E036-4EB1-A9F2-50D2D9756806

P577

Q30442046-66B63158-840C-4191-897F-6228B1F72EAF

P5875

Q30442046-3E14EA88-BF1B-4EE9-BA9A-4D9F6D8EC184

P698

Q30442046-9D8CB513-9586-4ADC-B523-990BD2AA0788

P921

Q30442046-0954D900-C3A9-4EAD-8127-2C344537ED13

Q30442046-CF7EAD84-F976-4F22-9009-AA05BE18A76D

P356

JIMMUNOL.177.10.7435

P1433

Journal of Immunology

P1476

Thrice-weekly low-dose rituxim ...... chronic lymphocytic leukemia.

@en

P2093

Adam D Kennedy

http://www.w3.org/2001/XMLSchema#string

Andrew W Pawluczkowycz

http://www.w3.org/2001/XMLSchema#string

Jane C Eggleton

http://www.w3.org/2001/XMLSchema#string

John J Densmore

http://www.w3.org/2001/XMLSchema#string

Margaret A Lindorfer

http://www.w3.org/2001/XMLSchema#string

Michael E Williams

http://www.w3.org/2001/XMLSchema#string

Paul V Beum

http://www.w3.org/2001/XMLSchema#string

Ronald P Taylor

http://www.w3.org/2001/XMLSchema#string

Susan H Hamil

http://www.w3.org/2001/XMLSchema#string

P304

7435-7443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.177.10.7435

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6713635

http://www.w3.org/2001/XMLSchema#string

P698

17082663

http://www.w3.org/2001/XMLSchema#string

P921